FibroBiologics Files Patent for Oral Fibroblast Delivery System Targeting GI Tract Diseases

A provisional patent filing by FibroBiologics, Inc. signals a formulation challenge that CMOs and cell therapy manufacturing teams will need to track: delivering viable fibroblasts and fibroblast-derived materials through the gastric environment and into targeted intestinal regions via an oral route. The application, filed with the U.S. Patent and Trademark Office (USPTO) on May 18, 2026, is titled "Oral Fibroblasts and Fibroblast-Derived Therapeutics and Delivery Systems for Same."

The disclosed platform covers a broad therapeutic payload class, including whole cells, spheroids, extracellular vesicles, conditioned media, and genetically modified fibroblast variants. Delivery architecture described in the application incorporates multilayer encapsulation using hydrogels, nanoparticles, protective intermediate layers, and pH-sensitive enteric coatings engineered to bypass gastric acid and digestive enzymes before releasing payloads in targeted intestinal segments.

For formulation and process development teams, the GMP implications are non-trivial. Maintaining cell viability through encapsulation, drying or suspension processes, and cold-chain logistics introduces sterility assurance and process validation considerations that differ substantially from conventional biologics manufacturing. Scalable encapsulation of live cells under 21 CFR Part 211 and emerging cell therapy GMP frameworks will require close alignment between formulation science and quality systems.

The application identifies potential indications across a range of chronic gastrointestinal disorders, including inflammatory bowel disease, Crohn's disease, ulcerative colitis, irritable bowel syndrome, celiac disease, peptic ulcer disease, gastritis, and gastrointestinal cancers. FibroBiologics holds more than 270 issued and pending patents across multiple therapeutic areas, and this provisional filing extends that portfolio into oral delivery modalities not previously covered.

Chief Scientific Officer Hamid Khoja, Ph.D., noted that the application covers engineered fibroblast variants and programmable release concepts alongside whole-cell formats, positioning the platform as a framework for multiple product configurations rather than a single candidate. That breadth has direct consequences for how manufacturing processes and analytical methods would need to be qualified across payload types.

The transition from provisional to full patent prosecution, alongside any IND-enabling work, will be the next measurable checkpoint for assessing how this oral delivery architecture advances toward clinical and manufacturing readiness.

Source: FibroBiologics, Inc. via GlobeNewswire, May 18, 2026.